Journal: Molecular Medicine Reports
Article Title: CD8 + T cell‑related KCTD5 contributes to malignant progression and unfavorable clinical outcome of patients with triple‑negative breast cancer
doi: 10.3892/mmr.2024.13290
Figure Lengend Snippet: KCTD5 expression and prognosis in TNBC samples. (A) Expression of KCTD5 in TNBC and normal samples of GSE38959 dataset. (B) KCTD5 expression in cancers based on Tumor IMmune Estimation Resource database. (C) Kaplan-Meier OS curve. (D) Comparison of KCTD5 expression levels between TNBC and normal cell line determined by qPCR using a human normal breast epithelial cell line MCF10A and two human TNBC cell lines, MDA-MB-231 and MDA-MB-453. (E) Comparison of KCTD5 protein levels between TNBC and normal cell line detected by western blot based on normal cell line MCF10A and two human TNBC cell lines, MDA-MB-231 and MDA-MB-453. *P<0.05, **P<0.01 and ***P<0.001 vs. normal samples. TPM, transcripts per million; KCTD5, potassium channel tetramerization domain 5; TNBC, triple negative breast cancer.
Article Snippet: A human normal breast epithelial cell line MCF10A and two human TNBC cell lines, MDA-MB-231 and MDA-MB-453, were purchased from Procell Life Science & Technology Co., Ltd.
Techniques: Expressing, Comparison, Western Blot